Literature DB >> 2807372

Expression of a gp33/27,000 MW activation inducer molecule (AIM) on human lymphoid tissues. Induction of cell proliferation on thymocytes and B lymphocytes by anti-AIM antibodies.

P Sánchez-Mateos1, M Cebrián, A Acevedo, M López-Botet, M O De Landázuri, F Sánchez-Madrid.   

Abstract

We have recently described several monoclonal antibodies (mAb) that recognize a heterodimeric structure (gp33/27,000 MW) expressed on the surface of human peripheral blood T lymphocytes upon activation with different mitogenic stimuli. Such mAb, when used in combination with submitogenic doses of phorbol ester, were capable of triggering T-cell proliferation. The antigen has been designated as activation inducer molecule (AIM). In the present study we have investigated the expression of the AIM in different lymphoid and non-lymphoid tissues. In addition, we have analysed the ability of lymphocyte subsets derived from thymus and tonsil to proliferate in response to anti-AIM mAb. The presence of AIM on subpopulations of lymphoid cells from thymus, tonsil, lymph node and spleen has been demonstrated by immunoprecipitation, flow cytometry and immunoperoxidase staining of tissue sections. By contrast, non-lymphoid cells from tissue such as brain, kidney, liver, lung or skin did not react with anti-AIM mAb. In thymus, the AIM expression was restricted to a subset of CD3+ medullary thymocytes, whereas CD1+ CD3- cortical thymocytes did not express this antigen. Nevertheless, the majority of both purified CD1- and CD3- thymocytes expressed AIM antigen after treatment with PMA. In tonsil and lymph node, a strong staining of a subset of CD3+ T lymphocytes located in the germinal centre was observed by immunohistochemical labelling with anti-AIM mAb. Certain T cells from the paracortical zone and CD19+ B lymphocytes from mantle region were also reactive. Both purified tonsillar T and B lymphocytes strongly expressed AIM after activation with PMA. The anti-AIM mAb was able to induce a strong proliferative response on purified CD1- thymocytes as well as on both purified tonsillar T and B lymphocytes in the presence of submitogenic doses of PMA. By contrast, no proliferative response was induced through the AIM in the CD3- immature thymocyte subset.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2807372      PMCID: PMC1385507     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  33 in total

1.  Isolation of pure IgG1, IgG2a and IgG2b immunoglobulins from mouse serum using protein A-sepharose.

Authors:  P L Ey; S J Prowse; C R Jenkin
Journal:  Immunochemistry       Date:  1978-07

2.  Expression and function of AIM, an activation inducer molecule of human lymphocytes, is dependent on the activation of protein kinase C.

Authors:  M Cebrián; J M Redondo; A López-Rivas; G Rodríguez-Tarduchy; M O De Landázuri; F Sánchez-Madrid
Journal:  Eur J Immunol       Date:  1989-05       Impact factor: 5.532

3.  Characterization of antigen recognized by the monoclonal antibody (4F2): different molecular forms on human T and B lymphoblastoid cell lines.

Authors:  M E Hemler; J L Strominger
Journal:  J Immunol       Date:  1982-08       Impact factor: 5.422

4.  A monoclonal antibody that appears to recognize the receptor for human T-cell growth factor; partial characterization of the receptor.

Authors:  W J Leonard; J M Depper; T Uchiyama; K A Smith; T A Waldmann; W C Greene
Journal:  Nature       Date:  1982-11-18       Impact factor: 49.962

5.  Two monoclonal anti-human T lymphocyte antibodies have similar biologic effects and recognize the same cell surface antigen.

Authors:  G F Burns; A W Boyd; P C Beverley
Journal:  J Immunol       Date:  1982-10       Impact factor: 5.422

Review 6.  Human T lymphocyte antigens as defined by monoclonal antibodies.

Authors:  B F Haynes
Journal:  Immunol Rev       Date:  1981       Impact factor: 12.988

7.  Biochemical studies of the human thymocyte cell-surface antigens T6, T9 and T10.

Authors:  C Terhorst; A van Agthoven; K LeClair; P Snow; E Reinherz; S Schlossman
Journal:  Cell       Date:  1981-03       Impact factor: 41.582

8.  Characterization of a monoclonal antibody (4F2) that binds to human monocytes and to a subset of activated lymphocytes.

Authors:  B F Haynes; M E Hemler; D L Mann; G S Eisenbarth; J Shelhamer; H S Mostowski; C A Thomas; J L Strominger; A S Fauci
Journal:  J Immunol       Date:  1981-04       Impact factor: 5.422

9.  Ubiquitous cell-surface glycoprotein on tumor cells is proliferation-associated receptor for transferrin.

Authors:  R Sutherland; D Delia; C Schneider; R Newman; J Kemshead; M Greaves
Journal:  Proc Natl Acad Sci U S A       Date:  1981-07       Impact factor: 11.205

10.  Human cell surface glycoprotein related to cell proliferation is the receptor for transferrin.

Authors:  I S Trowbridge; M B Omary
Journal:  Proc Natl Acad Sci U S A       Date:  1981-05       Impact factor: 11.205

View more
  10 in total

Review 1.  Surface molecules involved in B lymphocyte function.

Authors:  P Möller; A Eichelmann; G Moldenhauer
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1991

2.  Induction of CD69 expression by cagPAI-positive Helicobacter pylori infection.

Authors:  Naoki Mori; Chie Ishikawa; Masachika Senba
Journal:  World J Gastroenterol       Date:  2011-08-28       Impact factor: 5.742

3.  Inhibiting CARD11 translation during BCR activation by targeting the eIF4A RNA helicase.

Authors:  James J Steinhardt; Raymond J Peroutka; Krystyna Mazan-Mamczarz; Qing Chen; Simone Houng; Carol Robles; Rolf N Barth; Joseph DuBose; Brandon Bruns; Ronald Tesoriero; Deborah Stein; Raymond Fang; Nader Hanna; Jason Pasley; Carlos Rodriguez; Mark D Kligman; Matthew Bradley; Joseph Rabin; Stacy Shackelford; Bojie Dai; Ari L Landon; Thomas Scalea; Ferenc Livak; Ronald B Gartenhaus
Journal:  Blood       Date:  2014-10-15       Impact factor: 22.113

4.  Development of a Monoclonal Antibody to Pig CD69 Reveals Early Activation of T Cells in Pig after PRRSV and ASFV Infection.

Authors:  Yunfei Tian; Yuxin Hao; Maoli Dong; Shuai Li; Dongyue Wang; Fei Jiang; Qingqing Wang; Xiaoli Hao; Yi Yang; Nanhua Chen; Jianzhong Zhu; Junqing Guo; Jiajun Wu; Shaobin Shang; Jiyong Zhou
Journal:  Viruses       Date:  2022-06-20       Impact factor: 5.818

5.  CD69 downregulates autoimmune reactivity through active transforming growth factor-beta production in collagen-induced arthritis.

Authors:  David Sancho; Manuel Gómez; Fernando Viedma; Enric Esplugues; Mónica Gordón-Alonso; María Angeles García-López; Hortensia de la Fuente; Carlos Martínez-A; Pilar Lauzurica; Francisco Sánchez-Madrid
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

6.  Upregulated expression and function of VLA-4 fibronectin receptors on human activated T cells in rheumatoid arthritis.

Authors:  A Laffón; R García-Vicuña; A Humbría; A A Postigo; A L Corbí; M O de Landázuri; F Sánchez-Madrid
Journal:  J Clin Invest       Date:  1991-08       Impact factor: 14.808

Review 7.  CD69 is the crucial regulator of intestinal inflammation: a new target molecule for IBD treatment?

Authors:  Katarina Radulovic; Jan Hendrik Niess
Journal:  J Immunol Res       Date:  2015-02-22       Impact factor: 4.818

8.  Nickel challenge up regulates CD69 expression on T lymphocyte sub-sets from patients with nickel induced contact dermatitis.

Authors:  Shakoor Zahid; Adam Mustafa; Assiri Dina; Bakry Sawsan; AlMarshad Felwa; GadElRab Mohammed; Abdulaziz Hasan
Journal:  Afr Health Sci       Date:  2019-03       Impact factor: 0.927

9.  The Conserved Non-Coding Sequence 2 (CNS2) Enhances CD69 Transcription through Cooperation between the Transcription Factors Oct1 and RUNX1.

Authors:  Miguel G Fontela; Laura Notario; Elisenda Alari-Pahissa; Elena Lorente; Pilar Lauzurica
Journal:  Genes (Basel)       Date:  2019-08-28       Impact factor: 4.096

10.  B cell activation and proliferation increase intracellular zinc levels.

Authors:  Johanna Ollig; Veronika Kloubert; Kathryn M Taylor; Lothar Rink
Journal:  J Nutr Biochem       Date:  2018-10-26       Impact factor: 6.048

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.